All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Amgen, Autolus, Jazz Pharmaceuticals, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View ALL content recommended for you
PK model predicts peg-asparaginase inactivation in ALL
Results from a Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 study analyzing asparaginase enzyme activity (AEA) pharmacokinetics in 644 patients aged 1–45 years with acute lymphoblastic leukemia (ALL) were recently published in the British Journal of Haematology by Dam et al. The study included 3,003 AEA samples collected 14 days post polyethylene glycol (peg)-asparaginase doses, with additional sampling between doses from February 2017 to December 2022 across Nordic and Baltic countries.
Key data: The incidence of inactivation was 15.2%. Mean AEA trough concentration (Ctrough) after the initial dose was significantly lower in patients with subsequent inactivation vs those without inactivation (79 international units per liter [iu/L] vs 174 iu/L; p < 0.001). The pharmacokinetic (PK) model demonstrated 87.8% sensitivity and 65.5% specificity for detecting increased peg-asparaginase clearance over time in patients experiencing inactivation.
Key learning: A validated PK model can identify increased clearance preceding inactivation in patients with ALL treated with intramuscular peg-asparaginase, enabling potential early intervention before clinical manifestation of hypersensitivity reactions and treatment failure.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your perception of incorporating blinatumomab into upfront ALL treatment regimens alongside traditional chemotherapy and pegaspargase?
